GCK对高脂饲料诱导的小鼠肥胖模型的降脂减肥作用
Inhibition of GCK on High Fat Diet-Induced Mouse Obesity
DOI: 10.12677/HJFNS.2020.91001, PDF,   
作者: 毛剑琴, 钟晓芳:浙江海正药业股份有限公司,浙江 台州;刘礼飞*:浙江海正药业股份有限公司,浙江 台州;武汉光谷亚太医药研究院有限公司,湖北 武汉
关键词: 人参皂苷复合物K小鼠肥胖模型降脂减肥脂代谢相关基因Ginsenoside Compound k Mouse Obesity Model Fat Loss Lipid Metabolism-Related Gene
摘要: 目的:探讨GCK对高脂饲料诱导的小鼠肥胖模型的干预作用。方法:小鼠用高脂饲料喂养12个月造成肥胖模型。GCK口服给药6周,同时记录小鼠摄食量、体重变化;实验终点处死小鼠取血浆,全自动生化仪检测血浆中ALT、AST、TC、TG水平;取肝脏制作石蜡切片HE染色后显微镜下观察肝脏中脂肪滴含量;肝脏匀浆提取RNA,RT-PCR检测脂代谢相关蛋白FAS和PPARα水平。结果:GCK不影响小鼠摄食量,但是高剂量GCK能够导致肥胖小鼠体重减少;GCK能够有效降低小鼠血浆ALT、AST、TC、TG水平;GCK能够减少小鼠肝脏中的脂肪含量,其作用机制可能是诱导FAS的降低和PPARα的升高。结论:GCK能够在一定程度上抑制高脂饲料造成的肥胖。
Abstract: Objective: To investigate the effect of GCK on high fat diet-induced mouse obesity model. Methods: Mice were fed a high-fat diet for 12 months to develop an obesity model. GCK was intragastrical administered for 6 weeks, while the food intake and body weight were recorded. The mice were sacrificed at the end of the experiment. The plasma levels of ALT, AST, TC and TG were detected by automatic biochemical analyzer. The liver was prepared by paraffin section and stained by HE staining kit. The RNA was extracted from the liver homogenate, and the levels of lipid metabolism related proteins FAS and PPARα were detected by RT-PCR. Results: GCK did not affect the food in-take of mice, but high dose of GCK could cause weight loss in obese mice. GCK can effectively reduce plasma ALT, AST, TC, TG levels in mice; GCK can reduce the fat content in mouse liver. The mechanism of those effects may be to induce the FAS decrease and PPARα increase. Conclusion: GCK can inhibit the HFD-induced obesity.
文章引用:毛剑琴, 钟晓芳, 刘礼飞. GCK对高脂饲料诱导的小鼠肥胖模型的降脂减肥作用[J]. 食品与营养科学, 2020, 9(1): 1-7. https://doi.org/10.12677/HJFNS.2020.91001

参考文献

[1] Bluher, M. (2019) Obesity: Global Epidemiology and Pathogenesis. Nature Reviews Endocrinology, 15, 288-298.
[Google Scholar] [CrossRef] [PubMed]
[2] Shin, Y.W. and Kim, D.H. (2005) Antipruritic Effect of Ginse-noside Rb1 and Compound K in Scratching Behavior Mouse Models. Journal of Pharmacological Sciences, 99, 83-88.
[Google Scholar] [CrossRef
[3] Joh, E.H., Lee, I.A., Jung, I.H., et al. (2011) Ginsenoside Rb1 and Its Metabolite Compound K Inhibit IRAK-1 Activation—The Key-Step of Inflammation. Biochemical Pharmacology, 82, 278-286.
[Google Scholar] [CrossRef] [PubMed]
[4] Kim, K., Park, M., Lee, Y.M., et al. (2014) Ginsenoside Metabolite Compound K Stimulates Glucagon-Like Peptide-1 Secretion in NCI-H716 Cells via Bile Acid Receptor Activation. Archives of Pharmacal Research, 37, 1193-1200.
[Google Scholar] [CrossRef] [PubMed]
[5] Kim, S., Kang, B.Y., Cho, S.Y., et al. (2004) Compound K In-duces Expression of Hyaluronan Synthase 2 Gene in Transformed Human Keratinocytes and Increases Hyaluronan in Hairless Mouse Skin. Biochemical and Biophysical Research Communications, 316, 348-355.
[Google Scholar] [CrossRef] [PubMed]
[6] Lee, H.U., Bae, E.A., Han, M.J., et al. (2005) Hepatoprotective Effect of Ginsenoside Rb1 and Compound K on Tert-Butyl Hydroperoxide-Induced Liver Injury. Liver International, 25, 1069-1073.
[Google Scholar] [CrossRef] [PubMed]
[7] 张雷明, 傅风华, 王天, 等. 人参皂苷CK对四氯化碳致大鼠慢性肝损伤的影响[J]. 时珍国医国药, 2006(1): 38-39.
[8] 聂忠富, 孙小燕, 张太平, 等. 人参皂苷Compound K对动脉粥样硬化大鼠氧化应激、炎症因子和血管活性物质的影响[J]. 河北中医, 2019, 41(7): 1042-1047.
[9] Riveros-McKay, F., Mistry, V., Bounds, R., et al. (2019) Genetic Architecture of Human Thinness Compared to Severe Obesity. PLOS Genetics, 15, e1007603.
[Google Scholar] [CrossRef] [PubMed]
[10] Sugden, M.C., Bulmer, K., Gibbons, G.F., et al. (2002) Pe-roxisome-Proliferator-Activated Receptor-Alpha (PPARalpha) Deficiency Leads to Dysregulation of Hepatic Lipid and Carbohydrate Metabolism by Fatty Acids and Insulin. Biochemical Journal, 364, 361-368.
[Google Scholar] [CrossRef] [PubMed]
[11] Item, F., Wueest, S., Lemos, V., et al. (2017) Fas Cell Surface Death Receptor Controls Hepatic Lipid Metabolism by Regulating Mitochondrial Function. Nature Communications, 8, Article No. 480.
[Google Scholar] [CrossRef] [PubMed]